Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPUS-1 cenerimod phase 3 study in systemic lupus erythematosus
2024-515870-28-00Phase 3Authorised
- Sponsor
- Viatris
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Cenerimod plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: SRI-4 response at Month 12. Planned start Oct 2024; status: authorised.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-515870-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515870-28-00.